Medpace Holdings stock holds at USD 604.25 as analysts stay at Hold

Published on 10/08/2026 at 07:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medpace Holdings stock's Q2 revenue reached USD 707.33 million, up 17.2 percent year over year. July EPS beat consensus by USD 0.27, while 13 analysts held a Hold consensus.

MEDP, US58506Q1094, Illustration mit AI erstellt.

Medpace Holdings, Inc. (ISIN US58506Q1094) was last at USD 604.25 on Nasdaq on October 7, 2026, with a 0.22 percent daily gain. The latest analyst view kept the stock at a Hold consensus, while the next quarterly report is scheduled for October 21.

USD 602.27 consensus target

According to MarketBeat on October 1, 2026, 13 analysts covered Medpace with three Buy ratings and ten Holds. The average 12-month target was USD 602.27, below the USD 604.25 price, with individual targets spanning USD 535 to USD 673.

The narrow gap between the average target and the October 7 market price puts valuation at the center of the current debate. The consensus target is USD 2.02 below the latest price, while the upper target is USD 68.75 higher.

Q2 revenue rose 17.2 percent

Medpace reported second-quarter 2026 revenue of USD 707.33 million, up 17.2 percent from USD 603.3 million in the comparable quarter, according to MarketBeat. Quarterly EPS was USD 4.25 versus USD 3.98 consensus, a USD 0.27 beat, and the company set fiscal 2026 EPS guidance at USD 17.250 to USD 17.950.

That combination gives investors two measurable checkpoints for the next report: whether revenue growth remains in double digits and whether earnings can stay above the current fiscal-year guidance midpoint of USD 17.600.

October 21 results set the next test

Business Wire reported on September 22, 2026, that Medpace will publish third-quarter results after the market close on October 21, 2026. The company plans its earnings call for October 22, 2026, at 9:00 a.m. ET.

The dates matter because the current share price sits USD 73.65 below the 52-week high of USD 677.90 and USD 231.25 above the 52-week low of USD 373.00. The range leaves the upcoming revenue and EPS figures as the next concrete test of the valuation.

Market value reaches USD 16.9 billion

Medpace had a market capitalization of USD 16.9 billion on October 7, 2026. Its trading volume was 207,570 shares, against an average volume of 276,388 shares, giving the latest session a measurable liquidity reference without changing the Hold consensus.